MacroGenics, Inc. (MGNX)
- Previous Close
16.10 - Open
15.99 - Bid 16.06 x 100
- Ask 16.10 x 300
- Day's Range
15.82 - 16.38 - 52 Week Range
4.29 - 21.88 - Volume
567,634 - Avg. Volume
1,579,353 - Market Cap (intraday)
1.005B - Beta (5Y Monthly) 2.11
- PE Ratio (TTM)
-- - EPS (TTM)
-0.15 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
24.78
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
www.macrogenics.comRecent News: MGNX
Performance Overview: MGNX
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MGNX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MGNX
Valuation Measures
Market Cap
1.01B
Enterprise Value
810.14M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
17.41
Price/Book (mrq)
6.59
Enterprise Value/Revenue
14.16
Enterprise Value/EBITDA
401.66
Financial Highlights
Profitability and Income Statement
Profit Margin
-15.42%
Return on Assets (ttm)
-36.33%
Return on Equity (ttm)
-6.15%
Revenue (ttm)
58.75M
Net Income Avi to Common (ttm)
-9.06M
Diluted EPS (ttm)
-0.15
Balance Sheet and Cash Flow
Total Cash (mrq)
229.8M
Total Debt/Equity (mrq)
22.26%
Levered Free Cash Flow (ttm)
-25.04M
Research Analysis: MGNX
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: MGNX
Daily – Vickers Top Buyers & Sellers for 10/05/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 09/12/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 09/05/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 02/17/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.